Page 130 - Read Online

Gomaa et al. Advanced HCC: current and potential therapies

resin microsphere radioembolization of hepatocellular carcinoma Cucchetti A, Marinelli S, Pettinato C, Erroi V, Fiumana S.
across Barcelona clinic liver cancer stages: a European evaluation. Yttrium-90 radioembolization vs sorafenib for intermediate-locally
Hepatology 2011;54:868-78. advanced hepatocellular carcinoma: a cohort study with propensity
88. Mazzaferro V, Sposito C, Bhoori S, Romito R, Chiesa C, Morosi score analysis. Liver Int 2015;35:1036-47.
C, Maccauro M, Marchianò A, Bongini M, Lanocita R. Yttrium-90 91. Cho YY, Lee M, Kim HC, Chung JW, Kim YH, Gwak GY, Bae
radioembolization for intermediate-advanced hepatocellular SH, Heo J, Kim YJ. Radioembolization is a safe and effective
carcinoma: a phase 2 study. Hepatology 2013;57:1826-37. treatment for hepatocellular carcinoma with portal vein thrombosis: a
89. Kulik LM, Carr BI, Mulcahy MF, Lewandowski RJ, Atassi B, Ryu propensity score analysis. PLoS One 2016;11:e0154986.
RK, Sato KT, Benson A, Nemcek AA, Gates VL. Safety and efficacy 92. Salman A, Simoneau E, Hassanain M, Chaudhury P, Boucher LM,
of 90Y radiotherapy for hepatocellular carcinoma with and without Valenti D, Cabrera T, Nudo C, Metrakos P. Combined sorafenib
portal vein thrombosis. Hepatology 2008;47:71-81. and yttrium-90 radioembolization for the treatment of advanced
90. Gramenzi A, Golfieri R, Mosconi C, Cappelli A, Granito A, hepatocellular carcinoma. Curr Oncol 2016;23:e472-80.

122 Hepatoma Research ¦ Volume 3 ¦ June 15, 2017